| scholarly article | Q13442814 |
| P356 | DOI | 10.1128/JVI.00628-09 |
| P8608 | Fatcat ID | release_nommvvsfobavjhx5m7b23rtuxa |
| P932 | PMC publication ID | 2772784 |
| P698 | PubMed publication ID | 19706699 |
| P2093 | author name string | Celia A Schiffer | |
| Colombe Chappey | |||
| Madhavi Kolli | |||
| Eric Stawiski | |||
| P2860 | cites work | Structural and kinetic analysis of drug resistant mutants of HIV-1 protease | Q27619254 |
| Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes | Q27638967 | ||
| In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease | Q28367941 | ||
| Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. | Q28369030 | ||
| Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease | Q28378274 | ||
| Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors | Q28378860 | ||
| Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites | Q28379086 | ||
| Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors | Q28379411 | ||
| A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism | Q28469113 | ||
| Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss | Q28474984 | ||
| Human immunodeficiency virus reverse transcriptase and protease sequence database | Q29616403 | ||
| Nelfinavir mesylate: a protease inhibitor | Q33592439 | ||
| A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1 | Q33979107 | ||
| Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response | Q34012585 | ||
| Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy | Q34106209 | ||
| Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection | Q34330667 | ||
| Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors | Q34446445 | ||
| Mechanism of substrate recognition by drug-resistant human immunodeficiency virus type 1 protease variants revealed by a novel structural intermediate | Q34545639 | ||
| Determinants of the human immunodeficiency virus type 1 p15NC-RNA interaction that affect enhanced cleavage by the viral protease. | Q35889311 | ||
| Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease | Q37596952 | ||
| Resistance to human immunodeficiency virus type 1 protease inhibitors. | Q39559316 | ||
| Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients | Q39580564 | ||
| Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro | Q39684211 | ||
| Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1 | Q40469287 | ||
| In vitro selection and characterization of VX-478 resistant HIV-1 variants. | Q41750125 | ||
| Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure | Q42277211 | ||
| N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure | Q43250924 | ||
| Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites. | Q44103766 | ||
| Co-evolution of nelfinavir-resistant HIV-1 protease and the p1-p6 substrate | Q44629818 | ||
| Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens | Q44880086 | ||
| Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. | Q46491049 | ||
| The HIV-1 protease resistance mutation I50L is associated with resistance to atazanavir and susceptibility to other protease inhibitors in multiple mutational contexts | Q46601145 | ||
| Combating susceptibility to drug resistance: lessons from HIV-1 protease. | Q52560699 | ||
| Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy | Q73271748 | ||
| Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors | Q74220146 | ||
| Recent developments in HIV protease inhibitor therapy | Q77354774 | ||
| Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients | Q80336815 | ||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 16 | |
| P304 | page(s) | 11027-11042 | |
| P577 | publication date | 2009-08-12 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance | |
| P478 | volume | 83 |
| Q58577506 | Allosteric Site Inhibitor Disrupting Auto-Processing of Malarial Cysteine Proteases |
| Q35261045 | Clinical management of HIV drug resistance |
| Q36729996 | Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy. |
| Q28546549 | Deep sequencing of protease inhibitor resistant HIV patient isolates reveals patterns of correlated mutations in Gag and protease |
| Q43136211 | Drug-resistant HIV-1 protease regains functional dynamics through cleavage site coevolution. |
| Q34775654 | Features, processing states, and heterologous protein interactions in the modulation of the retroviral nucleocapsid protein function |
| Q41969970 | Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naïve HIV-infected patients |
| Q34304136 | HIV-1 Gag C-terminal amino acid substitutions emerging under selective pressure of protease inhibitors in patient populations infected with different HIV-1 subtypes |
| Q58597952 | HIV-1 Protease Uses Bi-Specific S2/S2' Subsites to Optimize Cleavage of Two Classes of Target Sites |
| Q42109902 | HIV-1 Protease and Substrate Coevolution Validates the Substrate Envelope As the Substrate Recognition Pattern. |
| Q27683192 | HIV-1 Protease-Substrate Coevolution in Nelfinavir Resistance |
| Q38032330 | Human Immunodeficiency Virus Gag and protease: partners in resistance |
| Q37017282 | Improving Viral Protease Inhibitors to Counter Drug Resistance |
| Q27335448 | In silico prediction of mutant HIV-1 proteases cleaving a target sequence |
| Q33698683 | Inference of Epistatic Effects Leading to Entrenchment and Drug Resistance in HIV-1 Protease. |
| Q35950846 | Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity |
| Q35260370 | Molecular Basis for Drug Resistance in HIV-1 Protease |
| Q35237575 | Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance. |
| Q91995163 | Novel Protease Inhibitors Containing C-5-Modified bis-Tetrahydrofuranylurethane and Aminobenzothiazole as P2 and P2' Ligands That Exert Potent Antiviral Activity against Highly Multidrug-Resistant HIV-1 with a High Genetic Barrier against the Emerge |
| Q36414162 | Novel two-round phenotypic assay for protease inhibitor susceptibility testing of recombinant and primary HIV-1 isolates. |
| Q41775697 | Positive impact of HIV-1 gag cleavage site mutations on the virological response to darunavir boosted with ritonavir |
| Q42240414 | Quantitative assessment of in vivo HIV protease activity using genetically engineered QD-based FRET probes |
| Q34526179 | Structural basis and distal effects of Gag substrate coevolution in drug resistance to HIV-1 protease |
| Q27678853 | Structural, kinetic, and thermodynamic studies of specificity designed HIV-1 protease |
| Q36104509 | The Continuing Evolution of HIV-1 Therapy: Identification and Development of Novel Antiretroviral Agents Targeting Viral and Cellular Targets |
| Q27663608 | The Effect of Clade-Specific Sequence Polymorphisms on HIV-1 Protease Activity and Inhibitor Resistance Pathways |
Search more.